Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In COLUMBUS, treatment with encorafenib plus binimetinib in patients with advanced BRAF-mutant melanoma showed improved progression-free and overall survival with favourable tolerability compared to vemurafenib treatment. Here, results on health-related quality of life (HRQoL) are presented.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur J Cancer

Title: European journal of cancer (Oxford, England : 1990)

Publisher: Elsevier BV

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): Jul 2021

Volume: 152

Affiliations

[1 ] National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece. Electronic address: helgogas@gmail.com.

[2 ] University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.

[3 ] Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.

[4 ] Hospital Clinic of Barcelona, Barcelona, Spain.

[5 ] Unit of Medical Oncology, University of Perugia, Perugia, Italy.

[6 ] National Institute of Oncology, Budapest, Hungary.

[7 ] Eberhard Karls University, Tuebingen, Germany.

[8 ] University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.

[9 ] University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic.

[10 ] Hannover Medical School, Hannover, Germany.

[11 ] Oncology Institute of Veneto IRCCS, Padua, Italy.

[12 ] University Hospital Centre Bordeaux, Hôpital Saint-André, Bordeaux, France.

[13 ] Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

[14 ] University Medical Center, Mainz, Germany.

[15 ] Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.

[16 ] Department of Medical Oncology, Isala Oncological Center, Zwolle, Netherlands.

[17 ] Pierre Fabre Medicament, Boulogne-Billancourt, France.

[18 ] At Time of Research: Pfizer Inc., Boulder, CO, USA.

[19 ] Institute Gustave Roussy, Villejuif, France.

[20 ] Massachusetts General Hospital, Boston, MA, USA.

Article

Publisher Item ID: S0959-8049(21)00274-4

DOI: 10.1016/j.ejca.2021.04.028

PubMed ID: 34091420

SO-VID: 20571a7c-092e-452a-a74d-41a138d5ceac

History

Keywords: Encorafenib plus binimetinib,BRAF(V600E−K) mutant Melanoma,BRAF/MEK inhibitors Combination,Health-related quality of life,Hospitalisation rate

Data availability:

Keywords: Encorafenib plus binimetinib, BRAF(V600E−K) mutant Melanoma, BRAF/MEK inhibitors Combination, Health-related quality of life, Hospitalisation rate

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).

Read this article at

Abstract

Related collections

Scientific Ocean Drilling Expedition Research Results

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 140

Cited by 3